Price History

Hover for the daily close. The dotted line marks the period open.

Compare AVTX with… →

AVTX Key Statistics

As of Sep 4, 2026

Trading

Open: $18.81
Previous Close: $19.00
Day's Range: 18.79–19.62
52-Week Range: 9.54–24.27
Volume: 633.20K
Beta: 0.79

Valuation

Market Cap: $1.03B
P/E Ratio: unprofitable
EPS (ttm): −4.46

Financials (FY)

Revenue (FY): $59.00K−86.62%
Net Income (FY): −$78.26M
Profit margin: 0.00%
Shares Outstanding: 53.63M
1-Year Return: +89.27%

Dividend and dates

Earnings Date: November 12, 2026estimated
Avg Volume: 1.24M

Only metrics the company reports are shown. Data provided by Yahoo Finance via yfinance. Updated daily.

AVTX Stock Return by Calendar Year

Calendar-year returns computed from daily closing prices. Partial years are shown muted and marked with an asterisk.

+263.64%−99.25%+5.89%

2016*2017201820192020202120222023202420252026*

Year	Return
2026 (partial year)	+5.89%
2025	+144.41%
2024	−18.35%
2023	−99.25%
2022	−75.29%
2021	−35.61%
2020	−51.02%
2019	+66.87%
2018	+0.94%
2017	+263.64%
2016 (partial year)	−78.80%

As of September 4, 2026.

AVTX Revenue and Earnings by Fiscal Year

FY ends December

RevenueNet income

2022202320242025

Fiscal year	Revenue	Net income	Net margin
2025	$59.00K	−$78.26M	−132642.4%
2024	$441.00K	−$35.13M	−7965.8%
2023	$1.92M	−$31.54M	−1639.5%
2022	$18.05M	−$41.66M	−230.8%

Fiscal year	Revenue	Gross profit	Operating income	Net income	Net margin
2025	$59.00K	$59.00K	−$72.93M	−$78.26M	−132642.4%
2024	$441.00K	$807.00K	−$40.87M	−$35.13M	−7965.8%
2023	$1.92M	$640.00K	−$23.44M	−$31.54M	−1639.5%
2022	$18.05M	$14.62M	−$37.44M	−$41.66M	−230.8%

Annual figures as reported, in the company's reporting currency. As of December 31, 2025.

AVTX Valuation vs Biotechnology Median

Median of 656 stocks

Metric	AVTX	Biotechnology median	vs median
Profit margin	0.00%	0.00%	0.0 pts above

Medians across 656 Biotechnology stocks that report the metric. Medians, not averages, so one outlier cannot move them. As of September 4, 2026.

Recent News

News provided by third-party sources. Not financial advice.

Analysis

Data-derived

Company Overview

Avalo Therapeutics, Inc. (AVTX) is capitalised at $1.03B on the latest close. It is classified in the Biotechnology industry, within the Healthcare sector. Headcount on file is 33.

Over the past 52 weeks the price has ranged from $9.54 to $24.27. AVTX last closed at $19.23 on September 4, 2026. That is +$0.23 (+1.21%) against the previous close. The latest close sits 101.57% above that 52-week low.

Financial Health

Fiscal 2025 revenue came to $59.00K. Against the prior fiscal year total of $441.00K, that is a change of −86.62%. The same year closed with a net loss of $78.26M. Profit margin runs at 0%. Earnings per share on a trailing basis come to −4.46.

Across the 4 fiscal years on file, revenue moves from $18.05M in 2022 to $59.00K in 2025. Of those 4 years, 0 report positive net income.

Valuation Assessment

The record shows negative trailing earnings, so no price-to-earnings ratio is published.

Beta against the wider market is reported at 0.79. Daily returns over the trailing 10 years annualize to a volatility of 165.09%. Over the trailing twelve months the price has returned +89.27%. Measured over 10 years, that is −47.13% a year compounded.

Growth & Income

No dividend is on file for AVTX.

Across the complete calendar years on file, 2017 returned +263.64% and 2023 returned −99.25%. Of the 9 complete calendar years on file, 4 finished higher. So far in 2026 the price is +5.89%.

Peer Comparison

Avalo Therapeutics, Inc. (AVTX) operates in the Biotechnology industry. Here is how it compares to its closest peers by market capitalization:

Company	Ticker	Market Cap	P/E Ratio
Avalo Therapeutics, Inc.	AVTX	$1.03B	—
Vertex Pharmaceuticals Incorporated	VRTX	$138.42B	32.5
Regeneron Pharmaceuticals, Inc.	REGN	$85.22B	20.5
argenx SE	ARGX	$64.25B	40.1

The Biotechnology industry average P/E ratio is 12.6x. Avalo Therapeutics, Inc. has no P/E ratio because it is not currently profitable.

Every figure above is read from this page's own data on each nightly rebuild. Informational only, not financial advice. As of September 4, 2026.

Related Biotechnology Stocks

VRTX

Vertex Pharmaceuticals Incorporated

$138.42B

REGN

Regeneron Pharmaceuticals, Inc.

$85.22B

ARGX

argenx SE

$64.25B

MRNA

Moderna, Inc.

$58.11B

RVMD

Revolution Medicines, Inc.

$45.01B

ONC

BeOne Medicines AG

$40.53B

View all Biotechnology stocks →

Popular Healthcare Stocks

LLY

Eli Lilly and Company

$1.02T

JNJ

Johnson & Johnson

$663.28B

ABBV

AbbVie Inc.

$453.19B

MRK

Merck & Co., Inc.

$370.89B

UNH

UnitedHealth Group Incorporated

$356.47B

View all Healthcare stocks →

About Avalo Therapeutics, Inc.

Avalo Therapeutics, Inc., a clinical stage biotechnology company, develops IL-1ß-based treatments for immune-mediated inflammatory diseases in the Unites States. Its lead product includes AVTX-009, a humanized monoclonal antibody that binds to interleukin-1ß, which is in phase 2 clinical trial to treat inflammatory diseases. The company was formerly known as Cerecor Inc. and changed its name to Avalo Therapeutics, Inc. in August 2021. Avalo Therapeutics, Inc. was incorporated in 2011 and is headquartered in Wayne, Pennsylvania.

Visit website →

Avalo Therapeutics, Inc. (AVTX) Stock Analysis